Archives
-
Nystatin and Spiroplasma: Evidence, Scope, and Limits
2026-10-08
A source-grounded overview of what Nystatin can and cannot reveal in Spiroplasma eriocheiris cell-entry research, with comparisons to Candida and Aspergillus evidence, conceptual applications, and key limitations.
-
GSH and GSSG Assay Kit in Tumor Redox Biology
2026-10-08
Explore how the GSH and GSSG Assay Kit can support reduced glutathione detection and redox state analysis in hypoxia-focused tumor research. This article connects paired glutathione measurements with immunometabolism while clarifying evidence limits, assay interpretation, and study-design considerations.
-
(-)-Blebbistatin: Evidence, Applications, and Limits
2026-10-07
(-)-Blebbistatin is a widely used research probe for studying non-muscle myosin II and actin-dependent mechanics. This overview separates supplier-reported mechanism and selectivity claims from peer-reviewed evidence, explains conceptual applications in cytoskeletal and cardiac research, and defines important limits on interpreting results.
-
Penicillin G Sodium: Evidence, Uses, and Limits
2026-10-07
Penicillin G Sodium is a natural penicillin antibiotic whose principal value comes from inhibiting bacterial cell wall biosynthesis in susceptible organisms. This overview separates established mechanism and reported applications from supplier-level claims, explains why susceptibility and resistance determine relevance, and clarifies why an unrelated canine cancer-cell study cannot be used as evidence for penicillin activity.
-
Amphotericin B in Biofilm Resistance Research
2026-10-06
This overview examines Amphotericin B as a membrane-active polyene antifungal antibiotic in the context of Candida albicans biofilms, autophagy, and drug resistance. It distinguishes supplier-reported mechanisms from findings in a 2025 study of PP2A signaling, while outlining evidence strength, translational relevance, and important applicability limits.
-
(-)-Blebbistatin in Mechanobiology Research
2026-10-06
(-)-Blebbistatin is a pharmacological tool for examining myosin II-dependent force generation, cytoskeletal remodeling, and actin–myosin coupling. This overview places the compound in the context of recent work showing GABA-independent, mechanically induced GABAB receptor activation. It distinguishes established biochemical and cellular findings from broader mechanistic interpretations, while outlining evidence limitations, optical confounds, receptor-specific questions, and the boundaries of translating a non-muscle myosin II perturbation into claims about mechanotransduction.
-
JNK-IN-7 and Infection-Driven Apoptosis
2026-10-05
JNK-IN-7 provides a selective JNK inhibitor framework for interpreting infection-associated apoptosis without treating all cell-death signals as equivalent. This article connects its covalent kinase mechanism with morphotype-specific findings in Candida krusei-exposed bovine mammary epithelial cells and highlights key evidence limitations.
-
β-NMN and the Next Era of Metabolic Translation
2026-10-05
β-NMN research is moving beyond NAD+ replenishment toward mechanism-aware studies of insulin secretion, mitochondrial signaling, and diabetic cardiac remodeling. This article interprets a 2026 mouse study linking NMN with SIRT3–GSK3β–Smad3 signaling, defines the translational evidence boundary, and explains how beta-Nicotinamide mononucleotide can support rigorous metabolic regulation research without being mistaken for a clinical intervention.
-
Vancomycin and Microbiota–Immune Research
2026-10-04
Vancomycin is a glycopeptide antibiotic with conceptual value in bacterial resistance and microbiota research, but the supplied ulcerative colitis study does not test vancomycin specifically. Its findings support a microbiota–metabolite–immune connection involving Lactobacillus acidophilus and ursodeoxycholic acid, while important limits remain around antibiotic specificity, animal-to-human translation, and clinical applicability.
-
Dimetridazole: From Mechanism to Translation
2026-10-03
A source-grounded perspective on Dimetridazole that connects mechanistic hypotheses, analytical validation, antimicrobial assay design, regulatory context, and translational evidence without overstating what current data prove.
-
Surface Adsorption and Hexetidine Antimicrobial Activity
2026-10-02
Moran and Addy showed that surface adsorption and reactions with chromogenic material can substantially alter the antibacterial activity of cationic antiseptic mouthwashes. Their comparative experiments placed Hexetidine (NSC-17764) in a distinct position: it showed little apparent adsorption to acrylic, yet its activity against Escherichia coli was reduced in the presence of tea and its inhibition zones were eliminated by washing.
-
Measuring Cancer Drug Responses In Vitro
2026-10-01
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measures capture different relationships between proliferative arrest and cell death. The framework provides a more precise basis for interpreting in vitro drug responses and for designing assays that separate cytostatic effects from genuine cytotoxicity.
-
Vancomycin Workflows for Resistance Research
2026-10-01
Translate Vancomycin’s D-Ala-D-Ala binding into reproducible MRSA susceptibility, resistance, and controlled gut-microbiome experiments. This workflow emphasizes stock handling, broth microdilution design, comparator selection, and troubleshooting so antibiotic pressure is not mistaken for an immune or ecological effect.
-
(-)-Blebbistatin: Reliable Assay Workflows
2026-09-30
Learn how (-)-Blebbistatin, SKU B1387, can help distinguish non-muscle myosin II–dependent mechanical effects from genuine cytotoxicity in viability, proliferation, and cardiac assays. This scenario-based guide covers assay compatibility, dosing, solvent control, data interpretation, and practical vendor-selection criteria.
-
DNMT3B and Neuroendocrine Plasticity in Prostate Cancer
2026-09-30
The reference study identifies DNMT3B as a regulator of therapy-associated lineage plasticity, linking neuroendocrine differentiation with stemness in advanced prostate cancer. Genetic suppression and pharmacologic inhibition reduced neuroendocrine prostate cancer growth in preclinical models, supporting DNMT3B as a mechanistically motivated target rather than a passive disease marker.